Datapoint: CVS Returns Eliquis to Preferred Formulary

Following an outcry over safety concerns, CVS will return Bristol Myers Squibb and Pfizer’s Eliquis to its national preferred formulary July 1, according to reporting from Modern Healthcare. The blood thinner was removed in January, with patients advised to switch to Johnson & Johnson’s Xarelto. This sparked pushback from providers, however, as abruptly switching blood thinners can pose health risks to patients. 90% of all insured lives currently have preferred access to Eliquis under the pharmacy benefit, to Xarelto’s 99%.

SOURCE: MMIT Analytics, as of 6/27/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today